KDM3A

Summary

KDM3A (lysine demethylase 3A, HGNC:20815) is a protein-coding gene on chromosome 2p11.2, encoding Lysine-specific demethylase 3A (Q9Y4C1). Histone demethylase that specifically demethylates ‘Lys-9’ of histone H3, thereby playing a central role in histone code.

Enables histone H3K9me/H3K9me2 demethylase activity; iron ion binding activity; and nuclear androgen receptor binding activity. Involved in androgen receptor signaling pathway; formaldehyde biosynthetic process; and positive regulation of DNA-templated transcription. Located in nucleoplasm. Implicated in cervical cancer and colon cancer. Biomarker of Ewing sarcoma; hepatocellular carcinoma; nasopharynx carcinoma; and prostate cancer.

Source: NCBI Gene 55818 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 211 total
• Druggable target: yes
• MANE Select transcript: NM_018433

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20815
Approved symbol	KDM3A
Name	lysine demethylase 3A
Location	2p11.2
Locus type	gene with protein product
Status	Approved
Aliases	TSGA, KIAA0742, JHMD2A
Ensembl gene	ENSG00000115548
Ensembl biotype	protein_coding
OMIM	611512
Entrez	55818

Gene structure

Transcript identifiers

Ensembl transcripts: 24 — 14 protein_coding, 5 retained_intron, 4 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000312912, ENST00000409064, ENST00000409556, ENST00000427678, ENST00000441719, ENST00000452034, ENST00000462197, ENST00000463013, ENST00000466058, ENST00000470160, ENST00000483866, ENST00000485171, ENST00000488971, ENST00000491383, ENST00000498528, ENST00000900197, ENST00000900198, ENST00000900199, ENST00000900200, ENST00000900201, ENST00000900202, ENST00000900203, ENST00000955942, ENST00000955943

RefSeq mRNA: 2 — MANE Select: NM_018433 NM_001146688, NM_018433

CCDS: CCDS1990

Canonical transcript exons

ENST00000312912 — 26 exons

Exon	Start	End
ENSE00001427049	86441371	86441444
ENSE00003479777	86485729	86485859
ENSE00003494208	86456805	86456877
ENSE00003507633	86491141	86491275
ENSE00003516178	86481930	86482102
ENSE00003555318	86470204	86470408
ENSE00003584782	86484942	86485029
ENSE00003591841	86456983	86457071
ENSE00003600266	86464053	86464216
ENSE00003600440	86455085	86455187
ENSE00003605435	86489520	86489659
ENSE00003622555	86489318	86489437
ENSE00003685493	86490881	86491057
ENSE00003694483	86451103	86451213
ENSE00003888685	86483987	86484158
ENSE00003889116	86477877	86478029
ENSE00003890418	86492039	86492716
ENSE00003891330	86478170	86478265
ENSE00003891384	86474776	86474990
ENSE00003892260	86449807	86449962
ENSE00003892294	86442018	86442233
ENSE00003892503	86478608	86478735
ENSE00003893448	86480167	86480362
ENSE00003893959	86482458	86482694
ENSE00003894883	86456442	86456566
ENSE00003895332	86466372	86466883

Expression profiles

Bgee: expression breadth ubiquitous, 300 present calls, max score 99.00.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 33.0328 / max 650.2037, expressed in 1810 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
21292	32.3542	1810
21293	0.6786	266

Top tissues by expression

300 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	99.00	gold quality
oocyte	CL:0000023	98.06	gold quality
calcaneal tendon	UBERON:0003701	97.73	gold quality
sperm	CL:0000019	97.25	gold quality
ventricular zone	UBERON:0003053	96.95	gold quality
male germ cell	CL:0000015	96.60	gold quality
sural nerve	UBERON:0015488	96.54	gold quality
upper leg skin	UBERON:0004262	96.25	gold quality
skin of leg	UBERON:0001511	95.86	gold quality
skin of abdomen	UBERON:0001416	95.62	gold quality
zone of skin	UBERON:0000014	95.11	gold quality
skin of hip	UBERON:0001554	94.90	gold quality
left testis	UBERON:0004533	94.65	gold quality
right testis	UBERON:0004534	94.30	gold quality
right lung	UBERON:0002167	94.21	gold quality
ganglionic eminence	UBERON:0004023	94.18	gold quality
embryo	UBERON:0000922	94.16	gold quality
tibial artery	UBERON:0007610	94.10	gold quality
popliteal artery	UBERON:0002250	94.09	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	93.85	gold quality
testis	UBERON:0000473	93.81	gold quality
colonic epithelium	UBERON:0000397	93.63	gold quality
artery	UBERON:0001637	93.56	gold quality
lower esophagus mucosa	UBERON:0035834	93.49	gold quality
muscle layer of sigmoid colon	UBERON:0035805	93.48	gold quality
tibial nerve	UBERON:0001323	93.46	gold quality
upper arm skin	UBERON:0004263	93.44	gold quality
descending thoracic aorta	UBERON:0002345	93.43	gold quality
aorta	UBERON:0000947	93.34	gold quality
lower esophagus	UBERON:0013473	93.23	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.87

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CREB1, E2F6, EPAS1, FOXN1, HIF1A, MBD2, NANOGP8, NCOA1, POU5F1, TCF12, TCF3, TFCP2L1, ZFP57

miRNA regulators (miRDB)

81 targeting KDM3A, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-LET-7A-5P	99.98	72.29	1790
HSA-LET-7B-5P	99.98	72.31	1790
HSA-LET-7C-5P	99.98	72.29	1790
HSA-LET-7E-5P	99.98	72.29	1790
HSA-LET-7F-5P	99.98	72.56	1784
HSA-LET-7G-5P	99.98	72.37	1784
HSA-LET-7I-5P	99.98	72.37	1788
HSA-MIR-98-5P	99.98	72.33	1787
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-LET-7D-5P	99.96	71.76	1632
HSA-MIR-4458	99.96	71.64	1650
HSA-MIR-128-3P	99.95	71.17	2484
HSA-MIR-216A-3P	99.95	71.19	2505
HSA-MIR-141-3P	99.94	72.79	2421
HSA-MIR-200A-3P	99.94	72.68	2420
HSA-MIR-4760-3P	99.93	70.50	2385
HSA-MIR-6508-5P	99.92	70.67	2465

Literature-anchored findings (GeneRIF, showing 40)

• These findings demonstrate that JMJD1A can be stimulated by hypoxia both in vitro and in vivo involving binding of HIF-1 to a specific HRE in the JMJD1A promoter. (PMID:18538129)
• Results show that many genes regulated by hypoxia and HIF-1alpha show patterns of induction with JMJD (Jumonji-domain containing)1A and JMJD2B demonstrating robust, and JMJD2C more modest, up-regulation by hypoxia. (PMID:18713068)
• histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF (PMID:18984585)
• Immunohistochemical staining has revealed that JMJD1A is widely expressed in tissues, even in cells that are not known to express the androgen receptor, and is significantly increased in smooth muscle cells upon hypoxia treatment. (PMID:19471969)
• Hypoxic regulation of JMJD1A acts as a signal amplifier to facilitate hypoxic gene expression, ultimately enhancing tumor growth. (PMID:19858293)
• Data show that the JMJD1A/ABH2 family of dioxygenases is highly sensitive to inhibition by carcinogenic nickel ions. (PMID:20042601)
• identification of genetic alterations & expression changes of LSD1, JHDM2A & GASC1 in prostate cancer (PC); as no genetic alterations & only modest expression changes were found, it is unlikely they play a major role in progression of PC (PMID:20127736)
• Jumonji domain containing 1A is a novel prognostic marker for colorectal cancer. (PMID:20823141)
• the increased expression of JMJD1A might be associated with the progression of kidney cancer. (PMID:21275466)
• Up-regulation of miR-155 in nasopharyngeal carcinoma is partly driven by LMP1 and LMP2A, and results in downregulation of JMJD1A. (PMID:21541331)
• our results suggest that JMJD1A is a sensitive recurrence marker, and JMJD1A can promote malignant transformation via epithelial-mesenchymal transition. (PMID:21607773)
• study demonstrates KDM3A is overexpressed in various types of cancer and directly activates transcription of HOXA1 through demethylation of histone H3K9 by binding to its promoter region (PMID:22020899)
• Findings suggest that both Ni(2+) and ascorbate can regulate the expression of histone demethylase JMJD1A, which is important for cancer development or inhibition. (PMID:22318714)
• KDM3A is recruited to the SLC2A3 locus in an HIF1-dependent manner and demethylates H3K9me2 so as to upregulate its expression. (PMID:22645302)
• Exposing cells to either chemical or cellular sources of (*)NO resulted in a significant increase in dimethyl Lys-9 on histone 3 (H3K9me2), the preferred substrate for KDM3A. (PMID:23546878)
• Our results suggest that LANA may play a role in regulation of epigenetic marks on the KSHV genome, which is in part through association with the histone demethylase KDM3A. (PMID:23576503)
• Data indicate that JMJD1A gene silencing abrogated the hypoxia-induced adrenomedullin (ADM) expression and inhibited HepG2 and Hep3B cell growth. (PMID:23583388)
• A single amino acid in KDM3A, T667, affects histone demethylase activity towards H3K9me1 and -me2. (PMID:23593242)
• Expression of JHDM2A was significantly increased but HDAC2, HDAC7, and SUV39H2 were significantly down-regulated in Systemic Sclerosis B cells relative to controls (PMID:23891737)
• JMJD1A forms a homodimer through its catalytic domains, bringing the two active sites close together (PMID:24214985)
• Studies identify the histone demethylase KDM3A as a new, miR-regulated, tumor promoter in Ewing Sarcoma. (PMID:24362521)
• data identify a novel pathway through which N-Myc causes neuroblastoma cell migration and invasion, and provide important evidence for further development of more potent JMJD1A/MALAT1 inhibitors for the prevention of tumor metastasis. (PMID:24742640)
• Studies found that JMJD1A was consistently and significantly downregulated at both RNA and protein levels in human germ cell tumors. (PMID:25071150)
• ACK1 interacts with KDM3A to regulate the mammary tumor oncogene HOXA1. (PMID:25148682)
• mitogen- and stress-activated protein kinase 1 (MSK1) specifically phosphorylates KDM3A at Ser264 (p-KDM3A), which is enriched in the regulatory regions of gene loci in the human genome. (PMID:25535969)
• Loss of JMJD1A expression is associated with liver fibrosis. (PMID:25609425)
• JMJD1A is phosphorylated at S265 by protein kinase A (PKA), and this is pivotal to activate the beta1-adrenergic receptor gene (Adrb1) and downstream targets including Ucp1 in brown adipocytes. (PMID:25948511)
• a critical role for JMJD1A in regulating proliferation and survival of prostate cancer cells by controlling c-Myc expression at transcriptional and post-translational levels (PMID:26279298)
• JMJD1A-MALAT1-MAPK signaling might participate in the JMJD1A-induced cell proliferation of gastric cancer. (PMID:26617828)
• These results indicate that the KDM3A-KLF2-IRF4 pathway plays an essential role in multiple myeloma cell survival and homing to the bone marrow, and therefore represents a therapeutic target. (PMID:26728187)
• JMJD1A could promote non-small cell lung cancer tumorigenesis (PMID:26945572)
• The KDM3A to PRM1 mRNA expression ratio can be used as a reliable marker of successful testicular sperm extraction in men with obstructive and non-obstructive azoospermia with 95% sensitivity. (PMID:27027467)
• Study identified KDM3A an H3K9me2 demethylase, as responsible for the H3K9me2 reduction and critical for breast tumor transformation. (PMID:27034728)
• depletion of KDM3A was capable of reactivating mutated p53 to induce the expression of pro-apoptotic genes in breast cancer with mutant p53. KDM3A knockdown also potently inhibited tumorigenic potentials of breast cancer stem-like cells and rendered them sensitive to apoptosis induced by chemotherapeutic drugs. (PMID:27270439)
• The authors find that KDM3A promotes anoikis through transcriptional activation of BNIP3 and BNIP3L, which encode pro-apoptotic proteins. (PMID:27472901)
• ormal stromal restricts cancer cell proliferation through JMJD1a-dependent modulation of gene expression. (PMID:27488962)
• deficient expression of JMJD1A/JMJD1A might be reflecting and/or contributing to round spermatid maturation arrest (PMID:27692601)
• our findings reveal a novel mechanism by which KDM3A promotes ovarian CSCs, proliferation and chemoresistance and thus, highlights the significance of KDM3A as a novel therapeutic target for resistant ovarian cancer. (PMID:27694900)
• In the present report, hypoxia is shown to activate a HIF-KDM3A-MMP12 signaling cascade that promotes trophoblast invasion and trophoblast-directed uterine spiral artery remodeling. (PMID:27807143)
• JMJD1A and c-Myc levels are independent prognostic factors for cervical cancer patients (PMID:27835890)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
mus_musculus	Kdm3a	ENSMUSG00000053470
rattus_norvegicus	Kdm3a	ENSRNOG00000007814
drosophila_melanogaster	Kdm3	FBGN0037703

Paralogs (3): KDM3B (ENSG00000120733), HR (ENSG00000168453), JMJD1C (ENSG00000171988)

Protein

Protein identifiers

Lysine-specific demethylase 3A — Q9Y4C1 (reviewed: Q9Y4C1)

Alternative names: JmjC domain-containing histone demethylation protein 2A, Jumonji domain-containing protein 1A, [histone H3]-dimethyl-L-lysine(9) demethylase 3A

All UniProt accessions (4): Q9Y4C1, C9J7Q7, C9JC73, F8WE62

UniProt curated annotations — full annotation on UniProt →

Function. Histone demethylase that specifically demethylates ‘Lys-9’ of histone H3, thereby playing a central role in histone code. Preferentially demethylates mono- and dimethylated H3 ‘Lys-9’ residue, with a preference for dimethylated residue, while it has weak or no activity on trimethylated H3 ‘Lys-9’. Demethylation of Lys residue generates formaldehyde and succinate. Involved in hormone-dependent transcriptional activation, by participating in recruitment to androgen-receptor target genes, resulting in H3 ‘Lys-9’ demethylation and transcriptional activation. Involved in spermatogenesis by regulating expression of target genes such as PRM1 and TNP1 which are required for packaging and condensation of sperm chromatin. Involved in obesity resistance through regulation of metabolic genes such as PPARA and UCP1.

Subunit / interactions. Interacts with VRK1.

Subcellular location. Cytoplasm. Nucleus.

Cofactor. Binds 1 Fe(2+) ion per subunit.

Domain organisation. The JmjC domain and the C6-type zinc-finger are required for the demethylation activity. Leu-Xaa-Xaa-Leu-Leu (LXXLL) motifs are known to mediate the association with nuclear receptors.

Similarity. Belongs to the JHDM2 histone demethylase family.

RefSeq proteins (2): NP_001140160, NP_060903* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003347	JmjC_dom	Domain
IPR045109	LSDs-like	Family
IPR054294	KDM3A/B_DUF7030	Domain
IPR054503	KDM3AB_Tudor	Domain
IPR054504	PWWP_KDM3B	Domain

Pfam: PF02373, PF22987, PF22988, PF22989

Enzyme classification (BRENDA):

• EC 1.14.11.65 — [histone H3]-dimethyl-L-lysine9 demethylase (BRENDA: 9 organisms, 67 substrates, 84 inhibitors, 4 Km, 4 kcat entries)

Substrate kinetics (BRENDA)

2 substrates with measured Km, best-characterized 2. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
[HISTONE H3]-N6,N6-DIMETHYL-L-LYSINE9	0.106–0.1061	2
[HISTONE H3]-N6-METHYL-L-LYSINE9	0.095–0.0952	2

Catalyzed reactions (Rhea), 1 shown:

• N(6),N(6)-dimethyl-L-lysyl(9)-[histone H3] + 2 2-oxoglutarate + 2 O2 = L-lysyl(9)-[histone H3] + 2 formaldehyde + 2 succinate + 2 CO2 (RHEA:60188)

UniProt features (31 total): sequence conflict 8, modified residue 5, sequence variant 5, binding site 3, region of interest 3, mutagenesis site 2, chain 1, domain 1, zinc finger region 1, short sequence motif 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y4C1-F1	69.06	0.34

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (3): 1249; 1120; 1122

Post-translational modifications (5): 264, 325, 445, 766, 895

Mutagenesis-validated functional residues (2):

Position	Phenotype
1120	abolishes lysine-specific histone demethylase activity.
1120	abolishes histone demethylase activity.

Function

Pathways and Gene Ontology

Reactome pathways

7 pathways

ID	Pathway
R-HSA-3214842	HDMs demethylate histones
R-HSA-9029569	NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux
R-HSA-162582	Signal Transduction
R-HSA-3247509	Chromatin modifying enzymes
R-HSA-4839726	Chromatin organization
R-HSA-9006931	Signaling by Nuclear Receptors
R-HSA-9024446	NR1H2 and NR1H3-mediated signaling

MSigDB gene sets: 346 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_MCMV_INFECTION_UP, E2F_Q4_01, TGCGCANK_UNKNOWN, CCAWYNNGAAR_UNKNOWN, GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_PAIRED_DONORS_WITH_INCORPORATION_OR_REDUCTION_OF_MOLECULAR_OXYGEN, GOBP_RESPONSE_TO_PEPTIDE, GOBP_CELLULAR_RESPONSE_TO_LIPID, MENSE_HYPOXIA_UP, FOXO4_01, GOBP_MALE_GAMETE_GENERATION, FOXO1_01, GGGTGGRR_PAX4_03, AATGGAG_MIR136, USF_C, EFC_Q6

GO Biological Process (17): regulation of transcription by RNA polymerase II (GO:0006357), spermatid nucleus elongation (GO:0007290), hormone-mediated signaling pathway (GO:0009755), androgen receptor signaling pathway (GO:0030521), positive regulation of DNA-templated transcription (GO:0045893), positive regulation of transcription by RNA polymerase II (GO:0045944), formaldehyde biosynthetic process (GO:0046293), positive regulation of cold-induced thermogenesis (GO:0120162), cellular response to leukemia inhibitory factor (GO:1990830), regulation of stem cell population maintenance (GO:2000036), regulation of stem cell differentiation (GO:2000736), chromatin organization (GO:0006325), chromatin remodeling (GO:0006338), spermatogenesis (GO:0007283), regulation of gene expression (GO:0010468), cell differentiation (GO:0030154), demethylation (GO:0070988)

GO Molecular Function (12): transcription coregulator activity (GO:0003712), iron ion binding (GO:0005506), zinc ion binding (GO:0008270), chromatin DNA binding (GO:0031490), histone H3K9 demethylase activity (GO:0032454), nuclear androgen receptor binding (GO:0050681), histone H3K9me/H3K9me2 demethylase activity (GO:0140683), chromatin binding (GO:0003682), protein binding (GO:0005515), oxidoreductase activity (GO:0016491), metal ion binding (GO:0046872), dioxygenase activity (GO:0051213)

GO Cellular Component (7): histone deacetylase complex (GO:0000118), chromatin (GO:0000785), male germ cell nucleus (GO:0001673), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-5 pathways:

Category	Pathways
Chromatin modifying enzymes	1
NR1H2 and NR1H3-mediated signaling	1
Chromatin organization	1
Signal Transduction	1
Signaling by Nuclear Receptors	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
regulation of DNA-templated transcription	2
transcription by RNA polymerase II	2
transition metal ion binding	2
binding	2
nucleus organization	1
spermatid nucleus differentiation	1
signal transduction	1
cellular response to hormone stimulus	1
nuclear receptor-mediated steroid hormone signaling pathway	1
DNA-templated transcription	1
positive regulation of RNA biosynthetic process	1
regulation of transcription by RNA polymerase II	1
positive regulation of DNA-templated transcription	1
small molecule biosynthetic process	1
aldehyde biosynthetic process	1
formaldehyde metabolic process	1
positive regulation of multicellular organismal process	1
cold-induced thermogenesis	1
regulation of cold-induced thermogenesis	1
cellular response to cytokine stimulus	1
response to leukemia inhibitory factor	1
stem cell population maintenance	1
regulation of developmental process	1
regulation of multicellular organismal process	1
regulation of cell differentiation	1
stem cell differentiation	1
cellular component organization	1
chromatin organization	1
developmental process involved in reproduction	1
male gamete generation	1
gene expression	1
regulation of macromolecule biosynthetic process	1
cellular developmental process	1
metabolic process	1
transcription regulator activity	1
DNA binding	1
chromatin binding	1
histone H3 demethylase activity	1
nuclear receptor binding	1

Protein interactions and networks

STRING

1316 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
KDM3A	SMARCA4	P51532	924
KDM3A	PPARG	P37231	879
KDM3A	PRM1	P04553	866
KDM3A	KDM4C	Q9H3R0	862
KDM3A	TNP1	P09430	855
KDM3A	KDM4B	O94953	836
KDM3A	KDM4A	O75164	827
KDM3A	NUPR1	O60356	809
KDM3A	KDM1A	O60341	805
KDM3A	HIF1A	Q16665	785
KDM3A	H3-3A	P06351	737
KDM3A	H3C14	Q71DI3	737
KDM3A	H3-5	Q6NXT2	737
KDM3A	H3C1	P02295	737
KDM3A	H3-4	Q16695	737
KDM3A	H3-7	Q5TEC6	737

IntAct

40 interactions, top by confidence:

A	B	Type	Score
RASSF6	STK4	psi-mi:“MI:0914”(association)	0.780
KDM3A	STAT1	psi-mi:“MI:0915”(physical association)	0.590
STAT1	KDM3A	psi-mi:“MI:0915”(physical association)	0.590
KDM3A	RPS6KA5	psi-mi:“MI:0915”(physical association)	0.540
RPS6KA5	KDM3A	psi-mi:“MI:0217”(phosphorylation reaction)	0.540
KDM3A	RPS6KA5	psi-mi:“MI:0217”(phosphorylation reaction)	0.540
TCEAL1	CHEK1	psi-mi:“MI:0914”(association)	0.530
KDM3A	RPS6KA5	psi-mi:“MI:0915”(physical association)	0.520
KDM3A	MYCBP	psi-mi:“MI:0915”(physical association)	0.400
LAMA3	KDM3A	psi-mi:“MI:0915”(physical association)	0.400
KDM3A	RIPK2	psi-mi:“MI:0915”(physical association)	0.370
Dut	NPAT	psi-mi:“MI:0914”(association)	0.350
POLR2F	BDP1	psi-mi:“MI:0914”(association)	0.350
Chmp3	DTL	psi-mi:“MI:0914”(association)	0.350
Chmp6	NSF	psi-mi:“MI:0914”(association)	0.350
ORF73	ECI2	psi-mi:“MI:0914”(association)	0.350
RASSF6	STK4	psi-mi:“MI:0914”(association)	0.350
TCEAL1	PDCD5	psi-mi:“MI:0914”(association)	0.350
CBX2	TRANK1	psi-mi:“MI:0914”(association)	0.350
CBX1	EXOC5	psi-mi:“MI:0914”(association)	0.350

BioGRID (87): KDM3A (Affinity Capture-MS), KDM3A (Affinity Capture-MS), TNK2 (Affinity Capture-Western), KDM3A (Affinity Capture-Western), ARFGAP2 (Co-fractionation), ARPP19 (Co-fractionation), GART (Co-fractionation), IRF2BP1 (Co-fractionation), KDM3A (Co-fractionation), KDM3A (Co-fractionation), KDM3A (Co-fractionation), KDM3A (Co-fractionation), KIAA0368 (Co-fractionation), KDM3A (Affinity Capture-MS), KDM3A (Affinity Capture-MS)

ESM2 similar proteins: A0A0R4IYX6, A0A1D5NVS8, A0A1L8H0H2, A0AVK6, A5GFT6, A7XYH5, A7XYJ6, B7ZS37, B8A5Y1, D4A666, E1B7L7, E1BKK0, E1BLP6, F1LMN3, F6YVB9, F8VPJ6, Q12766, Q13029, Q14B70, Q2HNT1, Q2HNT2, Q2KHR2, Q4V9H5, Q58FA4, Q5DTH5, Q5ZIE8, Q5ZIX8, Q5ZJ69, Q5ZM88, Q63679, Q63755, Q68FE9, Q69ZF8, Q6DRC5, Q6P4F7, Q6PCM1, Q6ZSZ6, Q76L83, Q80Y19, Q8BHZ4

Diamond homologs: C0SUU8, C0SV12, F4HZD1, Q15652, Q5HZN1, Q5ZIX8, Q63679, Q6IRB8, Q6PCM1, Q6ZPY7, Q7LBC6, Q8H1S7, Q8VYB9, Q9SSE9, Q9VHC5, Q9Y4C1, Q69ZK6, P97609, Q61645

SIGNOR signaling

11 interactions.

A	Effect	B	Mechanism
HIF1A	“up-regulates quantity by expression”	KDM3A	“transcriptional regulation”
EPAS1	“up-regulates quantity by expression”	KDM3A	“transcriptional regulation”
TNK2	“down-regulates activity”	KDM3A	phosphorylation
KDM3A	“up-regulates activity”	H3-2	demethylation
KDM3A	“up-regulates activity”	H3C15	demethylation
KDM3A	“up-regulates activity”	H3-3A	demethylation
KDM3A	“up-regulates activity”	H3-4	demethylation
KDM3A	“up-regulates activity”	H3-5	demethylation
JAK2	“up-regulates activity”	KDM3A	phosphorylation
NANOGP8	“down-regulates quantity by repression”	KDM3A	“transcriptional regulation”
2-oxoglutarate(2-)	“up-regulates activity”	KDM3A	“chemical activation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

211 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	139
Likely benign	19
Benign	15

Top pathogenic / likely-pathogenic (0)

SpliceAI

4162 predictions. Top by Δscore:

Variant	Effect	Δscore
2:86440948:TTG:T	donor_gain	1.0000
2:86440963:G:GG	donor_gain	1.0000
2:86449876:A:T	donor_gain	1.0000
2:86451101:A:AG	acceptor_gain	1.0000
2:86451102:G:GG	acceptor_gain	1.0000
2:86451102:GAC:G	acceptor_gain	1.0000
2:86455079:TTTCA:T	acceptor_loss	1.0000
2:86455080:TTCAG:T	acceptor_loss	1.0000
2:86455081:TCAG:T	acceptor_loss	1.0000
2:86455082:CA:C	acceptor_loss	1.0000
2:86455083:A:AG	acceptor_gain	1.0000
2:86455083:AG:A	acceptor_gain	1.0000
2:86455084:G:GG	acceptor_gain	1.0000
2:86455084:GG:G	acceptor_gain	1.0000
2:86455084:GGAT:G	acceptor_gain	1.0000
2:86455183:AAAAG:A	donor_loss	1.0000
2:86455184:AAAG:A	donor_loss	1.0000
2:86455185:AAG:A	donor_loss	1.0000
2:86455186:AG:A	donor_loss	1.0000
2:86455187:GG:G	donor_loss	1.0000
2:86455188:G:A	donor_loss	1.0000
2:86455189:T:A	donor_loss	1.0000
2:86456439:A:AG	acceptor_gain	1.0000
2:86456439:AAG:A	acceptor_gain	1.0000
2:86456439:AAGGT:A	acceptor_gain	1.0000
2:86456440:A:G	acceptor_gain	1.0000
2:86456441:G:GG	acceptor_gain	1.0000
2:86456441:GGT:G	acceptor_gain	1.0000
2:86456563:GGAG:G	donor_gain	1.0000
2:86456564:G:GT	donor_gain	1.0000

AlphaMissense

8702 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:86470272:T:C	F530L	1.000
2:86470273:T:C	F530S	1.000
2:86470274:C:A	F530L	1.000
2:86470274:C:G	F530L	1.000
2:86470280:G:C	Q532H	1.000
2:86470280:G:T	Q532H	1.000
2:86470290:T:A	C536S	1.000
2:86470290:T:C	C536R	1.000
2:86470291:G:A	C536Y	1.000
2:86470291:G:C	C536S	1.000
2:86470291:G:T	C536F	1.000
2:86470292:T:G	C536W	1.000
2:86470320:T:A	C546S	1.000
2:86470320:T:C	C546R	1.000
2:86470321:G:A	C546Y	1.000
2:86470321:G:C	C546S	1.000
2:86470321:G:T	C546F	1.000
2:86470322:C:G	C546W	1.000
2:86470329:T:A	C549S	1.000
2:86470329:T:C	C549R	1.000
2:86470330:G:C	C549S	1.000
2:86470331:T:G	C549W	1.000
2:86470386:T:A	C568S	1.000
2:86470386:T:C	C568R	1.000
2:86470386:T:G	C568G	1.000
2:86470387:G:A	C568Y	1.000
2:86470387:G:C	C568S	1.000
2:86470387:G:T	C568F	1.000
2:86470388:C:G	C568W	1.000
2:86470389:C:A	R569S	1.000

dbSNP variants (sampled 300 via entrez): RS1000034803 (2:86480915 C>G,T), RS1000069536 (2:86446620 G>T), RS1000212817 (2:86469625 CAT>C), RS1000307747 (2:86462746 G>A), RS1000323306 (2:86462810 T>C), RS1000348074 (2:86441936 C>G), RS1000376152 (2:86435217 A>C), RS1000560695 (2:86468806 G>A,C), RS1000576927 (2:86451333 A>T), RS1000619634 (2:86469536 C>T), RS1000713472 (2:86471246 AAT>A), RS1000733348 (2:86439140 T>A), RS1000801958 (2:86487024 G>A), RS1000820288 (2:86470800 T>C), RS1000835034 (2:86440025 A>G)

Disease associations

OMIM: gene MIM:611512 | disease phenotypes: MIM:608957

GenCC curated gene-disease

Mondo (2): susceptibility to respiratory infections associated with CD8alpha chain mutation (MONDO:0012161), prostate cancer (MONDO:0008315)

Orphanet (2): Susceptibility to respiratory infections associated with CD8alpha chain mutation (Orphanet:169085), Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST003139_21	Glomerular filtration rate in chronic kidney disease	6.000000e-06
GCST006061_54	Atrial fibrillation	3.000000e-10
GCST006061_55	Atrial fibrillation	4.000000e-11
GCST007239_5	Ovarian cancer	2.000000e-06

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750
C563824	CD8 Deficiency, Familial (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL1938209 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — 1.14.11.- Histone demethylases

Most potent curated ligand interactions (1 total), top 1:

Ligand	Action	Affinity	Parameter
IOX1	Inhibition	7.0	pIC50

ChEMBL bioactivities

32 potent at pChembl≥5 of 66 total, top 32 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.24	IC50	57	nM	CHEMBL3774692
6.85	IC50	140	nM	CHEMBL3108958
6.80	IC50	158.5	nM	CHEMBL1230640
6.77	IC50	170	nM	CHEMBL1230640
6.70	IC50	200	nM	CHEMBL1230640
6.40	IC50	400	nM	CHEMBL5173876
5.96	IC50	1100	nM	CHEMBL3108956
5.90	IC50	1259	nM	CHEMBL3621852
5.73	IC50	1850	nM	CHEMBL4592908
5.70	IC50	1995	nM	N-OXALYLGLYCINE
5.70	IC50	2020	nM	CHEMBL4585876
5.64	IC50	2300	nM	CHEMBL3775262
5.64	IC50	2300	nM	CHEMBL3786952
5.50	IC50	3162	nM	CHEMBL3621857
5.48	IC50	3300	nM	CHEMBL316034
5.32	IC50	4800	nM	CHEMBL3775899
5.28	IC50	5300	nM	CHEMBL3774537
5.25	IC50	5680	nM	CHEMBL4516101
5.24	IC50	5700	nM	CHEMBL3775867
5.24	IC50	5780	nM	CHEMBL4449500
5.21	IC50	6100	nM	CHEMBL3775894
5.21	IC50	6130	nM	CHEMBL4525269
5.19	IC50	6420	nM	CHEMBL4447515
5.10	IC50	7943	nM	CHEMBL3621854
5.10	IC50	7943	nM	CHEMBL3621855
5.10	IC50	7943	nM	CHEMBL316034
5.08	IC50	8300	nM	CHEMBL3775668
5.07	IC50	8500	nM	CHEMBL3183531
5.05	IC50	9000	nM	CHEMBL3775272
5.04	IC50	9100	nM	CHEMBL3108955
5.01	IC50	9700	nM	CHEMBL3108954
5.00	IC50	1e+04	nM	CHEMBL3621858

PubChem BioAssay actives

37 with measured affinity, of 137 total; 31 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-(2-amino-1,3-thiazol-4-yl)pyridine-4-carboxylic acid	1282553: Inhibition of KDM3A (unknown origin) using biotin-H3K9me2 (1 to 21 residues) as substrate preincubated for 15 mins followed by substrate addition measured after 5 mins by alphascreen assay	ic50	0.0570	uM
2-[4-[[4-[(1S,2R)-2-aminocyclopropyl]phenyl]carbamoyl]-2-pyridinyl]pyridine-4-carboxylic acid;2,2,2-trifluoroacetic acid	1066185: Inhibition of recombinant JMJD1A (unknown origin) incubated for 15 mins prior to substrate addition by AlphaScreen method	ic50	0.1400	uM
8-hydroxyquinoline-5-carboxylic acid	1249065: Inhibition of KDM3A (unknown origin)	ic50	0.1585	uM
2-(carboxymethylamino)-2-oxoacetic acid	1801992: Demethylase AlphaScreen Assay from Article 10.1038/nchembio.2087: “Structural analysis of human KDM5B guides histone demethylase inhibitor development.”	ic50	0.2900	uM
(E)-4-[2-(4-benzylpyridine-3-carbonyl)hydrazinyl]-4-oxobut-2-enoic acid	1916584: Inhibition of human KDM3A preincubated for 15 mins followed by substrate addition and measured after 5 mins using H3(1-21)K9Me2-GGK-Biotin peptide as substrate by AlphaScreen-based assay	ic50	0.4000	uM
2-[[[2-[2-(dimethylamino)ethyl-ethylamino]-2-oxoethyl]amino]methyl]pyridine-4-carboxylic acid	1801992: Demethylase AlphaScreen Assay from Article 10.1038/nchembio.2087: “Structural analysis of human KDM5B guides histone demethylase inhibitor development.”	ic50	0.7800	uM
2-(4-methoxycarbonyl-2-pyridinyl)pyridine-4-carboxylic acid	1066185: Inhibition of recombinant JMJD1A (unknown origin) incubated for 15 mins prior to substrate addition by AlphaScreen method	ic50	1.1000	uM
2-pyridin-2-ylpyridine-4-carboxylic acid	1249055: Inhibition of KDM3A (unknown origin) using H3(1-21)K9Me2-GGK-biotin substrate incubated for 5 mins by alpha screen assay	ic50	1.2589	uM
8-[4-[2-[4-[3-(pyrrolidin-1-ylmethyl)phenyl]piperidin-1-yl]ethyl]pyrazol-1-yl]-3H-pyrido[3,4-d]pyrimidin-4-one	1556106: Inhibition of KDM3A (unknown origin) by Alphascreen assay	ic50	1.8500	uM
8-[4-[2-[4-[4-[2-(dimethylamino)ethyl]phenyl]piperidin-1-yl]ethyl]pyrazol-1-yl]-3H-pyrido[3,4-d]pyrimidin-4-one	1556106: Inhibition of KDM3A (unknown origin) by Alphascreen assay	ic50	2.0200	uM
2-[2-hydroxy-5-[(4-hydroxybenzoyl)amino]phenyl]pyridine-4-carboxylic acid	1282316: Inhibition of KDM3A (unknown origin) expressed in Escherichia coli using H3 (1 to 21 residues) K9Me2-GGK-Biotin KDM3A Cognate Ligand/10 uM alpha-ketoglutarate as substrate/cofactor preincubated for 5 mins followed by substrate addition measured after 20 mins by alphascreen assay	ic50	2.3000	uM
2-[5-[(4-chloro-2-methylphenyl)methoxy]pyrazol-1-yl]pyridine-4-carboxylic acid	1391735: Inhibition of KDM3A (unknown origin)	ic50	2.3000	uM
ethyl 2-[[[2-[2-(dimethylamino)ethyl-ethylamino]-2-oxoethyl]amino]methyl]pyridine-4-carboxylate	1802660: AlphaScreen Assay from Article 10.1016/j.chembiol.2017.02.006: “Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells.”	ic50	3.0000	uM
2-[1-(2-phenylethyl)triazol-4-yl]pyridine-4-carboxylic acid	1249055: Inhibition of KDM3A (unknown origin) using H3(1-21)K9Me2-GGK-biotin substrate incubated for 5 mins by alpha screen assay	ic50	3.1623	uM
pyridine-2,4-dicarboxylic acid	1282316: Inhibition of KDM3A (unknown origin) expressed in Escherichia coli using H3 (1 to 21 residues) K9Me2-GGK-Biotin KDM3A Cognate Ligand/10 uM alpha-ketoglutarate as substrate/cofactor preincubated for 5 mins followed by substrate addition measured after 20 mins by alphascreen assay	ic50	3.3000	uM
8-[4-[2-[4-[(4-chlorophenyl)methyl]piperidin-1-yl]ethyl]pyrazol-1-yl]-3H-pyrido[3,4-d]pyrimidin-4-one	1282553: Inhibition of KDM3A (unknown origin) using biotin-H3K9me2 (1 to 21 residues) as substrate preincubated for 15 mins followed by substrate addition measured after 5 mins by alphascreen assay	ic50	4.8000	uM
8-[4-[2-[4-(3-chlorophenyl)piperidin-1-yl]ethyl]pyrazol-1-yl]-3H-pyrido[3,4-d]pyrimidin-4-one	1282553: Inhibition of KDM3A (unknown origin) using biotin-H3K9me2 (1 to 21 residues) as substrate preincubated for 15 mins followed by substrate addition measured after 5 mins by alphascreen assay	ic50	5.3000	uM
8-[4-[2-[4-[3-(pyrrolidin-1-ylmethyl)-5-(trifluoromethyl)phenyl]piperidin-1-yl]ethyl]pyrazol-1-yl]-3H-pyrido[3,4-d]pyrimidin-4-one	1556106: Inhibition of KDM3A (unknown origin) by Alphascreen assay	ic50	5.6800	uM
2-[2-hydroxy-5-[(5-methyl-1,2-oxazole-3-carbonyl)amino]phenyl]pyridine-4-carboxylic acid	1282316: Inhibition of KDM3A (unknown origin) expressed in Escherichia coli using H3 (1 to 21 residues) K9Me2-GGK-Biotin KDM3A Cognate Ligand/10 uM alpha-ketoglutarate as substrate/cofactor preincubated for 5 mins followed by substrate addition measured after 20 mins by alphascreen assay	ic50	5.7000	uM
8-[4-(2-spiro[1,2-dihydroindene-3,4’-piperidine]-1’-ylethyl)pyrazol-1-yl]-3H-pyrido[3,4-d]pyrimidin-4-one	1556106: Inhibition of KDM3A (unknown origin) by Alphascreen assay	ic50	5.7800	uM
8-[4-[2-[4-(3,5-dichlorophenyl)piperidin-1-yl]ethyl]pyrazol-1-yl]-3H-pyrido[3,4-d]pyrimidin-4-one	1282553: Inhibition of KDM3A (unknown origin) using biotin-H3K9me2 (1 to 21 residues) as substrate preincubated for 15 mins followed by substrate addition measured after 5 mins by alphascreen assay	ic50	6.1000	uM
8-[4-[1-(cyclobutylmethyl)piperidin-4-yl]pyrazol-1-yl]-3H-pyrido[3,4-d]pyrimidin-4-one	1556106: Inhibition of KDM3A (unknown origin) by Alphascreen assay	ic50	6.1300	uM
8-[4-[2-[4-(3-fluorophenyl)piperidin-1-yl]ethyl]pyrazol-1-yl]-3H-pyrido[3,4-d]pyrimidin-4-one	1556106: Inhibition of KDM3A (unknown origin) by Alphascreen assay	ic50	6.4200	uM
potassium 2-(1-ethyltriazol-4-yl)pyridine-4-carboxylate	1249055: Inhibition of KDM3A (unknown origin) using H3(1-21)K9Me2-GGK-biotin substrate incubated for 5 mins by alpha screen assay	ic50	7.9433	uM
potassium 2-[1-(3-methylphenyl)triazol-4-yl]pyridine-4-carboxylate	1249055: Inhibition of KDM3A (unknown origin) using H3(1-21)K9Me2-GGK-biotin substrate incubated for 5 mins by alpha screen assay	ic50	7.9433	uM
8-[4-[2-(4-thiophen-2-ylpiperidin-1-yl)ethyl]pyrazol-1-yl]-3H-pyrido[3,4-d]pyrimidin-4-one	1282553: Inhibition of KDM3A (unknown origin) using biotin-H3K9me2 (1 to 21 residues) as substrate preincubated for 15 mins followed by substrate addition measured after 5 mins by alphascreen assay	ic50	8.3000	uM
ethyl 3-[[2-pyridin-2-yl-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)pyrimidin-4-yl]amino]propanoate	2145035: Inhibition of KDM3A (2 to 1322 residues)(unknown origin) by Alphalisa assay	ic50	8.5000	uM
2-[2-hydroxy-5-[[2-(3-methoxyphenyl)acetyl]amino]phenyl]pyridine-4-carboxylic acid	1282316: Inhibition of KDM3A (unknown origin) expressed in Escherichia coli using H3 (1 to 21 residues) K9Me2-GGK-Biotin KDM3A Cognate Ligand/10 uM alpha-ketoglutarate as substrate/cofactor preincubated for 5 mins followed by substrate addition measured after 20 mins by alphascreen assay	ic50	9.0000	uM
N-[6-[4-[(1R,2S)-2-aminocyclopropyl]anilino]-6-oxohexyl]-8-hydroxyquinoline-5-carboxamide;hydrochloride	1066185: Inhibition of recombinant JMJD1A (unknown origin) incubated for 15 mins prior to substrate addition by AlphaScreen method	ic50	9.1000	uM
N-[5-[4-[(1R,2S)-2-aminocyclopropyl]anilino]-5-oxopentyl]-8-hydroxyquinoline-5-carboxamide;hydrochloride	1066185: Inhibition of recombinant JMJD1A (unknown origin) incubated for 15 mins prior to substrate addition by AlphaScreen method	ic50	9.7000	uM
2-[1-(2-phenoxyethyl)triazol-4-yl]pyridine-4-carboxylic acid	1249055: Inhibition of KDM3A (unknown origin) using H3(1-21)K9Me2-GGK-biotin substrate incubated for 5 mins by alpha screen assay	ic50	10.0000	uM

CTD chemical–gene interactions

86 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Oxygen	increases reaction, increases expression, affects binding	7
sodium arsenite	increases expression, affects expression, decreases expression	5
cobaltous chloride	increases expression, decreases reaction	4
Valproic Acid	affects expression, decreases expression, increases expression	4
nickel chloride	decreases reaction, increases expression	3
Air Pollutants	decreases expression, affects expression, increases abundance	2
Cisplatin	decreases expression, affects cotreatment	2
Ozone	affects cotreatment, increases oxidation, affects expression, increases abundance	2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	increases expression, decreases expression	2
Cadmium Chloride	increases expression, decreases expression	2
aristolochic acid I	decreases expression	1
GSK-J4	increases expression	1
FR900359	affects phosphorylation	1
dicrotophos	decreases expression	1
bufotalin	increases expression	1
chloroacetaldehyde	decreases expression	1
bisphenol A	affects expression	1
lead acetate	decreases expression	1
quercitrin	increases expression	1
arsenite	affects binding, decreases reaction	1
sodium bichromate	increases expression	1
zinc chloride	decreases reaction, increases expression	1
butyraldehyde	decreases expression	1
gossypol acetic acid	increases expression	1
cupric chloride	increases expression	1
nickel sulfate	increases expression	1
methacrylaldehyde	affects cotreatment, increases oxidation	1
testosterone-3-carboxymethyloxime-bovine serum albumin conjugate	decreases expression	1
cobalt oxide	increases expression	1
di-n-butylphosphoric acid	affects expression	1

ChEMBL screening assays

25 unique, capped per target: 25 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1942534	Binding	Inhibition of KDM3A	Lysine demethylases inhibitors. — J Med Chem

Cellosaurus cell lines

8 cell lines: 5 cancer cell line, 3 embryonic stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A3L6	SEES3-1V human KDM3A, clone1	Embryonic stem cell	Male
CVCL_A3L7	SEES3-1V human KDM3A, clone2	Embryonic stem cell	Male
CVCL_A3L8	SEES3-1V human KDM3A, clone3	Embryonic stem cell	Male
CVCL_B8J4	Abcam HCT 116 KDM3A KO	Cancer cell line	Male
CVCL_B8XY	Abcam MCF-7 KDM3A KO	Cancer cell line	Female
CVCL_B9LF	Abcam A-549 KDM3A KO	Cancer cell line	Male
CVCL_SU22	HAP1 KDM3A (-) 1	Cancer cell line	Male
CVCL_SU23	HAP1 KDM3A (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer